Clinical Study on Gimeracil and Oteracil Porassium Tablet Combined with Cisplatin in Chemotherapy of Advanced Gastric Cancer
刘鹏,张弘纲,秦燕,冯奉仪,卢辉山,胡晓桦,袁苏徐,庄志祥,黄建瑾,欧阳学农,王宝成,陈焰,陈蕾,韩军,于浩,娄冬华
DOI: https://doi.org/10.16386/j.cjpccd.issn.1004-6194.2012.03.048
2012-01-01
Abstract:Objective To evaluate the efficacy and safety of Gimeracil and Oteracil Porassium tablet/cisplatin combination in the treatment of untreated advanced gastric cancer.Methods This study was a multicenter,open,randomized and controlled clinical trial in subjects with advanced gastric cancer.In the test group,Gimeracil and Oteracil Porassium tablet was administered orally at 40 mg/m2,bid,from d1 to d21,cisplatin was combined at 60 mg/m2 on d8,the treatment was repeated every 35 days.In the control group,CF was given at 200 mg/d,combined with Fluorouracil 400 mg/m2 from d1 to d5,cisplatin was combined at 60 mg/m2 on d1,the treatment was repeated every 28 days.The patients were administerd 2-6 cycles of the first line chemotherapy.Results Of 177 cases,177 were eligible for the analysis of side effects and 143 for the time to progress(TTP)as the main end point with PPS analysis.As the main end point,mean TTP was 22.0 weeks(13.0-34.0 weeks)in the test group,compared with 12.5 weeks(8.0-24.0 weeks)in the control group.There was significant difference between the two groups(P= 0.002 0).The major adverse effects were nausea,vomting,diarrhea,there was no significant difference in Grade 3/4 adverse effects between the two groups(P0.05).Conclusions Gimeracil and Oteracil Porassium tablet/cisplatin combination may have significant efficacy and tolerable toxicity for untreated advanced gastric cancer patients.